Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its hepatitis B drug candidate, ATI-2173. There are several competitors developing treatments for ...

The U.S. capacity to battle hepatitis B and C has been leveled a devastating blow with the recent closure of the CDC’s ...

The company is dedicated to educating patients, providers, and others on new findings in chronic hepatitis B virus (HBV ... CAMs are a new class of drugs that affect the HBV lifecycle differently ...

Let's dive into the world of hepatitis A, B, C, D, and E – five viruses that can affect your liver, each with its own unique characteristics and challenges. ALSO READ: Role Of Diagnostics In ...